Sphera Funds Management Ltd. Stoke Therapeutics, Inc. Transaction History

Sphera Funds Management Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$7.07 - $15.69 $222,280 - $493,293	31,440 Added 20.0%	188,640 $1.74 Million
Q3 2022 Nov 14, 2022	BUY	$12.56 - $22.53 $1.97 Million - $3.54 Million	157,200 New	157,200 $2.02 Million
Q3 2021 Nov 15, 2021	SELL	$23.65 - $34.44 $5.51 Million - $8.03 Million	-233,135 Closed	0 $0
Q2 2021 Aug 17, 2021	BUY	$30.53 - $41.09 $2.52 Million - $3.39 Million	82,406 Added 54.67%	233,135 $7.85 Million
Q1 2021 May 17, 2021	BUY	$36.08 - $69.81 $5.44 Million - $10.5 Million	150,729 New	150,729 $5.85 Million
Q2 2020 Aug 13, 2020	SELL	$20.26 - $29.73 $552,166 - $810,261	-27,254 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$16.8 - $34.15 $3.85 Million - $7.82 Million	-229,126 Reduced 89.37%	27,254 $624,000
Q4 2019 Feb 13, 2020	SELL	$20.01 - $30.79 $1.8 Million - $2.77 Million	-90,000 Reduced 25.98%	256,380 $7.26 Million
Q3 2019 Nov 14, 2019	SELL	$20.53 - $37.72 $93,698 - $172,154	-4,564 Reduced 1.3%	346,380 $7.38 Million
Q2 2019 Aug 14, 2019	BUY	$25.53 - $29.17 $8.96 Million - $10.2 Million	350,944 New	350,944 $0

125

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $386M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.